Selecting appropriate excipients for paediatric dosage form − Paediatric excipients risk assessment (PERA) framework – Part 1
European Journal of Pharmaceutics and Biopharmaceutics · 2024-10 · 203 · 114458
DOI: 10.1016/j.ejpb.2024.114458 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2024-10. Verfasst von Smita Salunke und 11 weiteren Autor:innen. Beteiligte Einrichtung: European Paediatric Formulation Initiative (EUPFI), University College London School of Pharmacy, London WC1N 1AX, UK. Electronic address: s.salunke@…. Hauptthemen laut MEDLINE: Chemistry, Pharmaceutical, Dosage Forms, Excipients. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Excipients are often the major component of the formulation that critically affect the dosage form, manufacturing process, product performance, stability and safety. They exert different roles and functions in a dosage form. Selecting excipients with appropriate safety and tolerability is a major hurdle in paediatric formulation development. The suitability of a particular excipient will be dependent on the context of its use with regard to the paediatric age range, acute versus chronic use, and clinical risk-benefit of the disease, active and excipient. Scientists are encouraged to apply the principle of risk-benefit to assess the suitability of excipients to the specific paediatric population. Indicative list of parameters that should be taken into consideration and hierarchy of information sources when assessing the excipients risks is provided by regulatory agencies. However, the approach to be taken and details of how the risk evaluation should be undertaken are lacking. There is a need for a systematic approach to selection of excipients and assessment of the risk of excipient exposure. The Paediatric Excipients Risk Assessment (PERA) framework developed and proposed in this paper provides a structured, systematic decision-making framework via customizable tools and processes that can help to improve the transparency and communications on the selection and justification of use of excipients in a paediatric formulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- European Paediatric Formulation Initiative (EUPFI), University College London School of Pharmacy, London WC1N 1AX, UK. Electronic address: s.salunke@ucl.ac.uk.
- Novo Nordisk Inc., 300 North Beacon Street, Suite 501, Watertown, MA 02472, USA. Electronic address: vagr@novonordisk.com.
- Jenny Walsh Consulting, Nottingham, UK. Electronic address: jenny@jennywalshconsulting.com.
- University of Liverpool, Department of Women's and Children's Health, Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool L8 7SS, UK. Electronic address: tnunn100@hotmail.com.
- IPEC (International Pharmaceutical Excipients Council) and Colorcon Ltd, Dartford, UK. Electronic address: KHughes@colorcon.com.
- F. Hoffmann La Roche AG, Grenzacher Str. 124, CH-4070 Basel, Switzerland.
Zitieren
APA
Salunke, S., Agrawal, A., Walsh, J., Nunn, A., Hughes, K., Kuehl, P., Caivano, G., Clapham, D., Thompson, K., Rumondor, A., Enright, B., & Sherratt, P. (2024). Selecting appropriate excipients for paediatric dosage form − Paediatric excipients risk assessment (PERA) framework – Part 1. European Journal of Pharmaceutics and Biopharmaceutics, 203, 114458. https://doi.org/10.1016/j.ejpb.2024.114458
Vancouver
Salunke S, Agrawal A, Walsh J, Nunn A, Hughes K, Kuehl P, et al. Selecting appropriate excipients for paediatric dosage form − Paediatric excipients risk assessment (PERA) framework – Part 1. European Journal of Pharmaceutics and Biopharmaceutics. 2024;203:114458. doi:10.1016/j.ejpb.2024.114458
BibTeX
@article{Salunke2024,
author = {Salunke, Smita and Agrawal, Anjali and Walsh, Jennifer and Nunn, Anthony and Hughes, Kevin and Kuehl, Peter and Caivano, Grazia and Clapham, David and Thompson, Karen and Rumondor, Alfred and Enright, Brian and Sherratt, Philip},
title = {Selecting appropriate excipients for paediatric dosage form − Paediatric excipients risk assessment (PERA) framework – Part 1},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2024},
volume = {203},
pages = {114458},
doi = {10.1016/j.ejpb.2024.114458}
}
EUVIMED